WST Q1: Can 15% Organic Growth and 47% EPS Surge Sustain Through 2026?
West Pharmaceutical's Q1 beat drove raised full-year guidance, but the question is whether GLP-1 demand and margin expansion can hold at this pace
Key Takeaways
West Pharmaceutical reported Q1 2026 results on April 23 with net sales of $844.9M (up 21% reported, 15.3% organic) and adjusted diluted EPS of $2.13 (up 46.9% year-over-year). The company raised full-year 2026 net sales guidance to $3.295B-$3.350B from prior $3.215B-$3.275B and lifted adjusted EPS guidance to $8.40-$8.75 from $7.85-$8.20. Gross margin expanded 200 basis points to 35%, driven by operating leverage and favorable mix. The key question for Q2 is whether organic growth can sustain above 12% and whether gross margin holds above 34% as the year progresses.
West Pharmaceutical Services reported Q1 2026 earnings on April 23, 2026. Net sales reached $844.9M, up 21% year-over-year on a reported basis and 15.3% on an organic basis. Adjusted diluted EPS came in at $2.13, up 46.9% from $1.45 in Q1 2025. GAAP diluted EPS was $1.92, up 56.1% year-over-year.
The Two Core Metrics This Quarter
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Organic Sales Growth | 15.3% | — | Strong acceleration |
| Adjusted Diluted EPS | $2.13 | $1.45 | +46.9% YoY |
| Gross Margin | 35.0% | 33.0% | +200 bps |
Organic growth of 15.3% significantly outpaced the company's prior full-year guidance midpoint, which implied roughly 10-11% organic growth for 2026. The EPS surge of 47% reflects both top-line momentum and margin expansion.
What the Numbers Tell Us
The 15.3% organic growth in Q1 signals sustained demand for high-value biologics (HVB) packaging, particularly components used in GLP-1 drug delivery systems. West's proprietary elastomer formulations and NovaPure components have become critical infrastructure for the obesity and diabetes drug wave. The organic growth rate is the key thread metric because it strips out currency and M&A effects, showing pure demand momentum.
Gross margin expansion to 35% (up 200 basis points year-over-year) reflects operating leverage as the company scales production of higher-margin HVB products. The margin improvement validates management's multi-year thesis that mix shift toward biologics packaging would drive sustainable margin expansion. The 35% gross margin is the highest quarterly print in at least two years.
The raised full-year guidance is the most material signal. Management lifted the net sales midpoint by $62.5M (roughly 2% increase) and the adjusted EPS midpoint by $0.48 (roughly 6% increase). The EPS guidance raise outpaced the sales guidance raise, implying continued margin expansion through the year.
Conclusion: The Thread Is Confirming
Q1 2026 confirms the West Pharmaceutical growth acceleration thesis. Organic growth above 15% and gross margin at 35% both exceed the sustainability thresholds that would validate a multi-year re-rating. The company repurchased 1.2M shares for $297.6M during the quarter, signaling management confidence in the trajectory.
What to Watch in Q2 2026
Organic sales growth sustaining above 12% is the primary metric. A drop below 10% would suggest GLP-1 component demand is peaking earlier than expected. Gross margin holding above 34% is the secondary metric—any compression below 33% would indicate pricing pressure or unfavorable mix shift. Management commentary on HVB backlog and capacity expansion timelines will clarify whether the current pace is sustainable through 2027.